Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study-Reference-Cited by-同舟云学术

Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study

Published:2023-10 Issue:44 Volume:41 Page:6558-6564
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Krishna Susarla Sai,Jahagirdar Rahul^ORCID,Ghosh Uttam Kheya,Srikanth Bhatt S.,Prashanth S.,Rajapantula Vasudev,Satish M.,Rajashakar B.C.,Sandhya G.,Rajendra L.,Prasad Sahoo Devi,Kumar Kanakasapapathy Anand

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference26 articles.

1. WHO Position Paper on Measles Vaccines-April 2017; Weekly Epidemiological Record, April 2017 recommendations; 7 Jan 2019; Vol.37 (2):219-222 (Accessed on 12th April 2023). https://apps.who.int/iris/bitstream/handle/10665/255149/WER9217.pdf;jsessionid=DD65E80BBE24A5C5E722F215676804D2?sequence.

2. WHO Position Paper on Rubella Vaccines-July 2020; Weekly Epidemiological Record; 3 July 2020; No 27, 2020, 95, 301–324 (Accessed on 12th April 2023). https://www.who.int/publications/i/item/WHO-WER9527.

3. Rubella Fact Sheet, WHO, updated on 4 October 2019 (Accessed on 12th April 2023). https://www.who.int/news-room/fact-sheets/detail/rubella.

4. Measles and rubella strategic framework: 2021-2030 (Accessed on 12th April 2023). Measles and rubella strategic framework: 2021-2030 (who.int).

5. Roadmap to Measles and Rubella Elimination in India by 2023 (Accessed on 12th April 2023). https://cms.pib.gov.in/WriteReadData/userfiles/PIB%20Mumbai/Roadmap%20towards%20Measles%20and%20Rubella%20Elimination%20in%20India%20by%202023%20.pdf.